Central nervous system agents and erectile dysfunction.

Abstract

Several centrally acting agents have shown potential to improve erectile function in men with ED. They still lack adequate data in efficacy and tolerability. Nasal formulations of apomorphine and bremelanotide seem to be the most likely candidates for future approval. They may play a role, specifically in men who fail phosphodiesterase 5 (PDE5) therapy, are unable to take PDE5 inhibitors because of side effects, or are on nitrate therapy. This article reviews the centrally acting agents and the data on their efficacy.

• Authors: Rajeev Kumar, Ajay Nehra
• Journal: The Urologic clinics of North America (Urol Clin North Am) Vol. 38 Issue 2 Pg. 165-73 (May 2011) ISSN: 1558-318X [Electronic] United States
• PMID: 21621083 (Publication Type: Journal Article, Review)
• Copyright: 2011. Published by Elsevier Inc.

Chemical References

• Amino Acids
• Central Nervous System Agents
• Dopamine Agonists
• Melanocortins
• Peptides, Cyclic
• Phosphodiesterase 5 Inhibitors
• Serotonin Uptake Inhibitors
• Nitric Oxide
• alpha-MSH
• bremelanotide
• Apomorphine

Topics

• Amino Acids (administration & dosage, therapeutic use)
• Apomorphine (administration & dosage, therapeutic use)
• Central Nervous System Agents (administration & dosage, therapeutic use)
• Dopamine Agonists (therapeutic use)
• Erectile Dysfunction (drug therapy, physiopathology)
• Humans
• Male
• Melanocortins (administration & dosage, therapeutic use)
• Nitric Oxide (administration & dosage, therapeutic use)
• Penile Erection (drug effects)
• Peptides, Cyclic (administration & dosage, therapeutic use)
• Phosphodiesterase 5 Inhibitors (therapeutic use)
• Selective Serotonin Reuptake Inhibitors (administration & dosage, therapeutic use)
• alpha-MSH (administration & dosage, therapeutic use)